# Human Interferon-beta 1b protein (Recombinant) (STJP000324)

## GENERAL INFORMATION

| | |
|---|---|
| Product Type | Proteins |
| Host / Source | CHO Cells |

## PRODUCT PROPERTIES

| | |
|---|---|
| Formulation | Lyophilised from 0.2 Mu m filtered solution containing mM NaOAc pH.5. |
| Molecular Weight | Native Human Interferon-beta, generated by the proteolytic removal of the signal peptide and propeptide, the molecule has a calculated molecular mass of approximately 23 kDa. Recombinant Interferon-beta 1b is a monomeric protein consisting of 166 ami |
| Storage Instruction | Can be stored in working aliquots at°C-°C C for one month, or at-20°C C for six months, with a carrier protein without detectable loss of activity. Avoid repeated freeze/thaw cycles. NA |

## TARGET INFORMATION

| | |
|---|---|
| Gene ID | 3456 |
| Gene Symbol | IFNB1 |
| UniProt ID | IFNB_HUMAN |
| Immunogen Region | Mature chain |
| Immunogen Sequence | MTNKCLLQIA LLLCFSTTAL SMSYNLLGFL QRSSNFQCQK LLWQLNGRLE YCLKDRMNFD IPEEIKQLQQ FQKEDAALTI YEMLQNIFAI FRQDSSSTGW NETIVENLLA NVYHQINHLK TVLEEKLEKE DFTRGKLMSS LHLKRYYGRI LHYLKAKEYS HCAWTIVRVE ILRNFYFINR LTGYLRN NA |

## ADDITIONAL INFORMATION

| | |
|---|---|
| Note | STRICTLY FOR FURTHER RESEARCH USE ONLY (RUO). MUST NOT TO BE USED IN DIAGNOSTIC OR THERAPEUTIC APPLICATIONS. |




Following the initial culture period, islets were cultured for an additional 6–24 hours in CMRL 1066 containing antibiotics, 2 mM glutamine and one of the following supplements: 0. 5 mM sodium palmitate solubilized in 0. 5% (weight/volume) fatty acid and lipopolysaccaride free bovine serum albumin (BSA) ; recombinant human Interleukin 1beta (IL-1ß (50 units/ml) and Interferon-gamma (IFN-Gamma ) (1,000 units/ml) ; 100 mM hydrogen peroxide; 2 mM DETA/NO or 10 mM streptozotocin (STZ). To some of the groups 10 μM of Imatinib was added at different time points prior to the addition of test substances given above. To controls equal amounts of vehicle (DMSO) were supplemented.




Interferon gamma (IFN-Gamma ) 50 Mu l (100 ng/ml) was added to each dish in the experimental studies. The cytoplasmic and nuclear extracts were washed with ice-cold PBS and lysed in a 0. 5 ml/well lysis buffer (150 mmol/l NaCl, 20 mmol/l Tris, pH 7. 5,0. 1% Triton X-100, 1 mmol/l phenylmethylsulfonyl fluoride [PMSF] and 10 Mu g/ml aprotonin) as modified from the reports of Kim et al. and Moon et al. [




E) Recombinant Type III Interferons in the absence of CM at the same concentrations as found in the CM (IL-28A/IFN Lambda 2: 1500 pg/mL; IL-28B/IFN Lambda 3: 10 pg/mL; IL-29/IFN Lambda 1: 500 pg/mL) were added to JFH-1 infected Huh7. 5. 1 cells.




Venous blood was collected prior to chemotherapy or at least one month following chemotherapy. For the offspring (HLA haploidentical donors) , the routine blood tests, and liver and kidney function tests were normal and negative for hepatitis A virus-IgM, hepatitis B surface antigen antibody, hepatitis B e--hepatitis B core-hepatitis C virus (HCV) -HCV-IgG, Syphilis- and human immunodeficiency virus-. As reported in our previous study (2 atmosphere. On the day of culture, 1,000 U/ml human recombinant interferon-Gamma, 500 U/ml recombinant human interleukin (rhIL) -1 Alpha and 1,000 U/ml rhIL-2 (Quangang Pharmaceutical Co. , , , ) were added. Four days later, 1,000 U/ml rhIL-2 was added and the cells were transferred into a GT-T610 culture bag. Cell growth was observed every other day and cells were stained with 0. 4% trypan blue and the viable cells were counted. Following 18 days of culture, cells were infused once daily (>1×109 cells; viability rate, >95%). A cycle of treatment…